Strategic Transformation and Growth Prospects: Mayank Mamtani’s Buy Rating on Novavax
B.Riley Financial analyst Mayank Mamtani has maintained their bullish stance on NVAX stock, giving a Buy rating on November 13.Don't Miss our ...
Multiple Sclerosis News Today13h
AI tool aims to accelerate clinical trial patient recruitment
An AI tool called Muse aims to optimize clinical trial patient recruitment and accelerate the development of new therapies.
Business Insider16h
J.P. Morgan Keeps Their Buy Rating on Merck KGaA (0O14)
Sanofi, and Molecular Partners AG. According to TipRanks, Vosser has an average return of 5.0% and a 49.18% success rate on recommended stocks. Merck KGaA has an analyst consensus of Strong Buy, with ...